Assenagon Asset Management S.A. Sells 169 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Assenagon Asset Management S.A. reduced its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) by 0.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 24,481 shares of the medical equipment provider’s stock after selling 169 shares during the period. Assenagon Asset Management S.A.’s holdings in Zimmer Biomet were worth $2,979,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Clear Street Markets LLC bought a new position in Zimmer Biomet during the 4th quarter worth $27,000. Lazard Asset Management LLC raised its position in Zimmer Biomet by 70.5% during the 3rd quarter. Lazard Asset Management LLC now owns 283 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 117 shares during the last quarter. Dark Forest Capital Management LP bought a new position in Zimmer Biomet during the 1st quarter worth $35,000. Peoples Bank KS bought a new position in Zimmer Biomet during the 3rd quarter worth $48,000. Finally, KB Financial Partners LLC acquired a new stake in Zimmer Biomet during the 1st quarter worth about $49,000. 88.89% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the transaction, the vice president now owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.95% of the company’s stock.

Zimmer Biomet Price Performance

ZBH stock opened at $128.47 on Wednesday. The company has a market capitalization of $26.40 billion, a P/E ratio of 26.27, a price-to-earnings-growth ratio of 2.42 and a beta of 1.01. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $149.25. The business has a 50-day simple moving average of $125.94 and a two-hundred day simple moving average of $118.31.

Zimmer Biomet (NYSE:ZBHGet Free Report) last released its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.15 by $0.05. The business had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.88 EPS. Research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a dividend of $0.24 per share. The ex-dividend date is Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a yield of 0.75%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 19.63%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ZBH. TheStreet upgraded Zimmer Biomet from a “c” rating to a “b-” rating in a report on Thursday, February 8th. Barclays increased their price target on Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a report on Monday, February 12th. Truist Financial increased their price target on Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a report on Friday, February 9th. Canaccord Genuity Group reiterated a “hold” rating and set a $130.00 price target on shares of Zimmer Biomet in a report on Friday, February 23rd. Finally, Evercore ISI downgraded Zimmer Biomet from an “outperform” rating to an “inline” rating and decreased their price target for the stock from $135.00 to $125.00 in a report on Thursday, January 4th. One analyst has rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the stock. Based on data from, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $138.28.

Check Out Our Latest Stock Analysis on Zimmer Biomet

Zimmer Biomet Profile

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Recommended Stories

Want to see what other hedge funds are holding ZBH? Visit to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with's FREE daily email newsletter.